Geode Capital Management LLC Grows Stock Position in VolitionRx Limited (NYSE:VNRX)

Geode Capital Management LLC boosted its stake in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, HoldingsChannel reports. The fund owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC’s holdings in VolitionRx were worth $439,000 at the end of the most recent quarter.

Separately, Ground Swell Capital LLC grew its holdings in shares of VolitionRx by 78.8% in the third quarter. Ground Swell Capital LLC now owns 45,959 shares of the company’s stock worth $28,000 after purchasing an additional 20,249 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Cameron John Reynolds bought 139,811 shares of VolitionRx stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, with a total value of $99,615.48. Following the transaction, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 358,266 shares of company stock worth $204,212. 12.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently commented on VNRX. D. Boral Capital reiterated a “buy” rating and set a $5.00 price target on shares of VolitionRx in a report on Wednesday, January 8th. StockNews.com started coverage on shares of VolitionRx in a research note on Tuesday, January 7th. They set a “sell” rating for the company. Finally, Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Up 3.5 %

Shares of VolitionRx stock opened at $0.65 on Monday. The business has a 50 day moving average of $0.65 and a 200 day moving average of $0.66. VolitionRx Limited has a 52 week low of $0.43 and a 52 week high of $1.23. The company has a market cap of $60.42 million, a PE ratio of -1.81 and a beta of 1.20.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.